Skip to main content
Medical information Clinical review pending

Genetic Testing

OncoPro Colorectal Cancer Screen Circulating Tumor Cells Test

The OncoPro Colorectal Cancer Screen Circulating Tumor Cells Test detects circulating tumor cells (CTCs) in the blood, aiding in the early detection and monitoring of colorectal cancer.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
10 mL (8 mL minimum) of whole blood collected in a Lavender Top (EDTA) tube.
Results
Confirm with the laboratory before booking.
Preparation
No specific patient preparation is required. Ensure the preservative supplied in the sample collection kit is added to the tube immediately after collection. Do not refrigerate or freeze the sample.
Test priceKSh 70,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the OncoPro Colorectal Cancer Screen Circulating Tumor Cells Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Individuals with a family history of colorectal cancer.
  • ✓Patients experiencing symptoms suggestive of colorectal cancer (e.g., changes in bowel habits, rectal bleeding, unexplained weight loss).
  • ✓Individuals aged 50 years and older.
  • ✓Monitoring for recurrence after colorectal cancer treatment.
  • ✓Assessing treatment effectiveness.
02

In plain language

What this test helps you understand

This test helps in the early detection of colorectal cancer by identifying circulating tumor cells in the blood. It can also be used to monitor treatment response and detect cancer recurrence in patients previously diagnosed with colorectal cancer.
The OncoPro Colorectal Cancer Screen Circulating Tumor Cells Test is a diagnostic tool used to help detect colorectal cancer. It works by identifying circulating tumor cells (CTCs) in a blood sample. These cells can break away from a primary tumor and travel through the bloodstream. Detecting CTCs can provide valuable information for early diagnosis and monitoring the progression or recurrence of colorectal cancer. Early detection is crucial for improving treatment outcomes. This test is part of a comprehensive approach to cancer screening and management.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo specific patient preparation is required. Ensure the preservative supplied in the sample collection kit is added to the tube immediately after collection. Do not refrigerate or freeze the sample.
Sample10 mL (8 mL minimum) of whole blood collected in a Lavender Top (EDTA) tube.
MethodologyThe test involves analyzing a blood sample to identify and count circulating tumor cells using specialized laboratory techniques. Confirm with the laboratory before booking.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test detects the presence of CTCs but does not provide information about the specific type or stage of cancer. A positive result requires further investigation and confirmation with other diagnostic methods. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

CTCs are cancer cells that have detached from a primary tumor and entered the bloodstream. Detecting them can indicate the presence of cancer.
No, this test is a screening and monitoring tool. A positive result indicates the presence of CTCs and requires further diagnostic tests and consultation with a healthcare professional for a definitive diagnosis.
The blood sample must be collected in a specific tube, mixed with the provided preservative, and shipped immediately at room temperature (18°C to 22°C). Refrigeration or freezing is not permitted.
Discuss this test with your doctor to determine if it is appropriate for your individual health situation and risk factors.
A positive result means circulating tumor cells were detected in your blood sample. Your doctor will discuss the implications and recommend further steps, which may include additional tests or consultations.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp